Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Mrinalkanti Kundu

Mrinalkanti Kundu

TCG Lifesciences Pvt. Ltd., India

Title: Modeling, Synthesis and Biological Evaluation: Identification of Novel Small Molecule Drug-like Anti-cancer Therapeutics

Biography

Biography: Mrinalkanti Kundu

Abstract

As per World Cancer Report, ~14 million new cases of cancer occurred globally resulting ~15% of deaths in 2012 and over 100 cancers affect human being. Towards our research goal in improving the quality of life for the people suffering from cancer, we are working on two approaches:
A] DNA integrity is critical for proper cellular function & proliferation and has thus played a key role as successful molecular target for many of the drugs used in cancer therapeutics for decades. Targeting non-canonical DNA secondary structures such as G4s is now considered as an attractive approach toward drug intervention in anti-cancer therapy. Accordingly, significant research is in progress targeting G4 DNAs with small molecules,
hoping to inhibit cancer growth and having lesser side effects.
B] Protein-protein interaction (PPI) is of high importance in the regulation of cellular processes and is consequently implicated in the development of various disease states including cancer. The interaction between protein molecules leads to the formation of larger protein complexes performing a specific function and the first PPI inhibitor has entered in
clinical development.